CRDL

Cardiol Therapeutics Inc. Class A Common Shares

1.77

USD

-0.12

-6.35%

Sep 23, 15:56 UTC -4

Closed

After-Market

1.76

-0.01

-0.56%

CRDL Earnings Reports

Positive Surprise Ratio

CRDL beat 18 of 24 last estimates.

75%

Next Report

Date of Next Report

Nov 11, 2026

Estimate for Q3 26 (Revenue/ EPS)

-$0.08

Implied change from Q2 26 (Revenue/ EPS)

+60.00%

Implied change from Q3 25 (Revenue/ EPS)

-33.33%

Cardiol Therapeutics Inc. Class A Common Shares earnings per share and revenue

On Aug 12, 2026, CRDL reported earnings of -0.05 USD per share (EPS) for Q2 26, beating the estimate of -0.10 USD, resulting in a 53.31% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.50% price change (close before vs. close after earnings).

Looking ahead to Q3 26, 3 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 60.00% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Champions Oncology, Inc.

Report Date

Sep 10, 2026 For Q1 27

Estimate

-$0.01

Actual

-$0.03

Surprise

-194.12%

PharmaCyte Biotech, Inc. Common Stock

Report Date

Sep 14, 2026 For Q1 27

Estimate

Actual

-$0.54

Surprise

FAQ

What were Cardiol Therapeutics Inc. Class A Common Shares's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Cardiol Therapeutics Inc. Class A Common Shares reported EPS of -$0.05, beating estimates by 53.31%, and revenue of $0.00, 0% as expectations.

How did the market react to Cardiol Therapeutics Inc. Class A Common Shares's Q2 2026 earnings?

The stock price moved up 12.5%, changed from $1.52 before the earnings release to $1.71 the day after.

When is Cardiol Therapeutics Inc. Class A Common Shares expected to report next?

The next earning report is scheduled for Nov 11, 2026.

What are the forecasts for Cardiol Therapeutics Inc. Class A Common Shares's next earnings report?

Based on 3 analysts, Cardiol Therapeutics Inc. Class A Common Shares is expected to report EPS of -$0.08 and revenue of -- for Q3 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.